| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pleural Neoplasms | 6 | 2025 | 83 | 2.100 |
Why?
|
| Lung Neoplasms | 13 | 2026 | 1547 | 1.680 |
Why?
|
| Mesothelioma | 6 | 2024 | 95 | 1.440 |
Why?
|
| Esophageal Neoplasms | 8 | 2020 | 383 | 1.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2026 | 355 | 1.100 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2025 | 745 | 1.010 |
Why?
|
| Adenocarcinoma | 3 | 2023 | 964 | 0.720 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2025 | 817 | 0.670 |
Why?
|
| Genetic Therapy | 1 | 2025 | 715 | 0.640 |
Why?
|
| Lymph Nodes | 2 | 2012 | 357 | 0.600 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2025 | 2011 | 0.570 |
Why?
|
| Tumor Microenvironment | 7 | 2026 | 708 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2016 | 1268 | 0.480 |
Why?
|
| Transcriptome | 3 | 2019 | 1115 | 0.470 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1585 | 0.440 |
Why?
|
| Lymph Node Excision | 3 | 2012 | 158 | 0.440 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2025 | 615 | 0.420 |
Why?
|
| Acinetobacter | 1 | 2013 | 9 | 0.400 |
Why?
|
| Carbapenems | 1 | 2013 | 46 | 0.380 |
Why?
|
| Acinetobacter Infections | 1 | 2013 | 32 | 0.380 |
Why?
|
| Cell Line, Tumor | 10 | 2025 | 3717 | 0.360 |
Why?
|
| MicroRNAs | 2 | 2016 | 889 | 0.360 |
Why?
|
| Genomics | 6 | 2023 | 1618 | 0.350 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 51 | 0.350 |
Why?
|
| Stomach Neoplasms | 4 | 2023 | 567 | 0.340 |
Why?
|
| Esophagectomy | 4 | 2013 | 70 | 0.340 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 67 | 0.340 |
Why?
|
| Disease-Free Survival | 9 | 2017 | 899 | 0.340 |
Why?
|
| Robotics | 1 | 2012 | 102 | 0.320 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2022 | 970 | 0.320 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 397 | 0.320 |
Why?
|
| Immunotherapy | 4 | 2024 | 759 | 0.310 |
Why?
|
| Bacteremia | 1 | 2013 | 429 | 0.290 |
Why?
|
| B7-H1 Antigen | 4 | 2024 | 129 | 0.290 |
Why?
|
| Phosphoproteins | 3 | 2015 | 450 | 0.290 |
Why?
|
| Liver Neoplasms | 4 | 2022 | 1363 | 0.280 |
Why?
|
| Gene Expression Profiling | 4 | 2025 | 1807 | 0.270 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2019 | 41 | 0.270 |
Why?
|
| Thymus Neoplasms | 2 | 2019 | 39 | 0.270 |
Why?
|
| Hospital Mortality | 2 | 2012 | 1059 | 0.260 |
Why?
|
| RNA, Untranslated | 2 | 2020 | 109 | 0.250 |
Why?
|
| Humans | 38 | 2026 | 130441 | 0.230 |
Why?
|
| Aged | 15 | 2026 | 20888 | 0.230 |
Why?
|
| Middle Aged | 16 | 2026 | 28395 | 0.230 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2026 | 155 | 0.220 |
Why?
|
| Pneumonectomy | 3 | 2026 | 154 | 0.210 |
Why?
|
| Apoptosis | 3 | 2021 | 1828 | 0.210 |
Why?
|
| GPI-Linked Proteins | 1 | 2024 | 109 | 0.210 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 429 | 0.200 |
Why?
|
| Killer Cells, Natural | 1 | 2026 | 351 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2018 | 1071 | 0.200 |
Why?
|
| Treatment Outcome | 12 | 2026 | 12835 | 0.200 |
Why?
|
| Sequence Analysis, RNA | 1 | 2025 | 411 | 0.190 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 425 | 0.180 |
Why?
|
| Mice | 7 | 2025 | 18229 | 0.180 |
Why?
|
| CTLA-4 Antigen | 2 | 2023 | 65 | 0.180 |
Why?
|
| Female | 21 | 2026 | 70354 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 464 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 66 | 0.170 |
Why?
|
| Male | 18 | 2026 | 64473 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 500 | 0.170 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2021 | 20 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 116 | 0.170 |
Why?
|
| Neoplasm Staging | 4 | 2012 | 1280 | 0.170 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 6788 | 0.160 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 290 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 1 | 2022 | 134 | 0.160 |
Why?
|
| Genome, Human | 1 | 2017 | 1314 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 384 | 0.150 |
Why?
|
| Candidemia | 1 | 2020 | 43 | 0.150 |
Why?
|
| Povidone-Iodine | 1 | 2019 | 7 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 143 | 0.140 |
Why?
|
| Animals | 8 | 2025 | 33857 | 0.140 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2018 | 22 | 0.140 |
Why?
|
| Macrophages | 1 | 2022 | 660 | 0.140 |
Why?
|
| Mesoderm | 1 | 2018 | 104 | 0.130 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 1799 | 0.130 |
Why?
|
| Prognosis | 8 | 2020 | 4861 | 0.130 |
Why?
|
| Republic of Korea | 3 | 2012 | 44 | 0.130 |
Why?
|
| Cell Cycle | 1 | 2020 | 596 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 479 | 0.130 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 224 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 112 | 0.120 |
Why?
|
| Systems Biology | 1 | 2016 | 60 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 78 | 0.120 |
Why?
|
| Amino Acid Transport Systems | 1 | 2015 | 9 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2017 | 436 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 585 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 2289 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 88 | 0.120 |
Why?
|
| Adult | 9 | 2021 | 31121 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2025 | 3406 | 0.110 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 393 | 0.110 |
Why?
|
| Anastomosis, Surgical | 2 | 2013 | 176 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 336 | 0.110 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 196 | 0.110 |
Why?
|
| Transcription Factors | 4 | 2016 | 2423 | 0.110 |
Why?
|
| Signal Transduction | 4 | 2020 | 4670 | 0.100 |
Why?
|
| Risk Factors | 7 | 2026 | 10949 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 486 | 0.100 |
Why?
|
| Oncogenes | 1 | 2014 | 163 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2016 | 3676 | 0.100 |
Why?
|
| Proteomics | 3 | 2023 | 616 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 599 | 0.090 |
Why?
|
| Algorithms | 1 | 2019 | 1663 | 0.090 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2012 | 4 | 0.090 |
Why?
|
| Pharyngostomy | 1 | 2012 | 2 | 0.090 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2012 | 3 | 0.090 |
Why?
|
| Pyriform Sinus | 1 | 2012 | 8 | 0.090 |
Why?
|
| Jejunostomy | 1 | 2012 | 21 | 0.090 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2012 | 19 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 2 | 2026 | 402 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 710 | 0.090 |
Why?
|
| Mediastinum | 1 | 2012 | 44 | 0.090 |
Why?
|
| Survival Rate | 2 | 2020 | 2112 | 0.090 |
Why?
|
| Acute Lung Injury | 1 | 2012 | 68 | 0.090 |
Why?
|
| Retrospective Studies | 8 | 2024 | 17514 | 0.090 |
Why?
|
| Jejunum | 1 | 2012 | 123 | 0.090 |
Why?
|
| Models, Biological | 1 | 2016 | 1383 | 0.090 |
Why?
|
| Neck | 1 | 2011 | 140 | 0.080 |
Why?
|
| Esophagus | 1 | 2012 | 232 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 567 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2025 | 2826 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2012 | 334 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 242 | 0.080 |
Why?
|
| Time Factors | 4 | 2012 | 6201 | 0.080 |
Why?
|
| Pneumonia | 1 | 2012 | 340 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 619 | 0.070 |
Why?
|
| Neoplasms | 2 | 2024 | 2969 | 0.060 |
Why?
|
| Genotype | 1 | 2013 | 2589 | 0.060 |
Why?
|
| Mutation | 4 | 2018 | 6098 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2013 | 3113 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 5153 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 387 | 0.050 |
Why?
|
| Base Sequence | 2 | 2020 | 2734 | 0.050 |
Why?
|
| Gene Expression | 2 | 2017 | 1486 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2022 | 236 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2015 | 701 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2024 | 437 | 0.040 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2022 | 103 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 564 | 0.040 |
Why?
|
| Ribs | 1 | 2021 | 52 | 0.040 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 83 | 0.040 |
Why?
|
| beta Catenin | 1 | 2022 | 198 | 0.040 |
Why?
|
| Smoking | 1 | 2026 | 928 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 640 | 0.040 |
Why?
|
| Bone Diseases, Infectious | 1 | 2020 | 8 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2020 | 2464 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 59 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2022 | 410 | 0.040 |
Why?
|
| Endophthalmitis | 1 | 2020 | 49 | 0.040 |
Why?
|
| G1 Phase | 1 | 2020 | 68 | 0.040 |
Why?
|
| Joint Diseases | 1 | 2020 | 31 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 517 | 0.040 |
Why?
|
| Candida albicans | 1 | 2020 | 87 | 0.040 |
Why?
|
| Endocarditis | 1 | 2020 | 102 | 0.040 |
Why?
|
| Incidence | 2 | 2020 | 3313 | 0.040 |
Why?
|
| Pain | 1 | 2021 | 429 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2019 | 69 | 0.030 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 6 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 38 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 1388 | 0.030 |
Why?
|
| Pleura | 1 | 2018 | 27 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1824 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2018 | 92 | 0.030 |
Why?
|
| Heterografts | 1 | 2018 | 191 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 805 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2020 | 290 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 949 | 0.030 |
Why?
|
| Stem Cells | 1 | 2022 | 703 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 125 | 0.030 |
Why?
|
| Cytokines | 1 | 2022 | 1344 | 0.030 |
Why?
|
| Proteogenomics | 1 | 2018 | 111 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 254 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1483 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 358 | 0.030 |
Why?
|
| Antibodies | 1 | 2017 | 320 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 590 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 977 | 0.030 |
Why?
|
| Cetuximab | 1 | 2014 | 14 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 176 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 4715 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 352 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 722 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 715 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2014 | 231 | 0.020 |
Why?
|
| CpG Islands | 1 | 2014 | 334 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 382 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 4472 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 236 | 0.020 |
Why?
|
| Jugular Veins | 1 | 2012 | 71 | 0.020 |
Why?
|
| Carotid Artery, Common | 1 | 2012 | 59 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 1021 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2012 | 123 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2014 | 341 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2896 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 194 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 723 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2011 | 179 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 686 | 0.020 |
Why?
|
| Lung | 1 | 2018 | 1534 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 20727 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 3469 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 446 | 0.020 |
Why?
|
| United States | 1 | 2025 | 11874 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 1209 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 1150 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1374 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 756 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 713 | 0.020 |
Why?
|
| Patient Selection | 1 | 2011 | 722 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 5034 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 1073 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1793 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 6424 | 0.020 |
Why?
|
| Length of Stay | 1 | 2012 | 1400 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2060 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 9993 | 0.010 |
Why?
|
| Biomarkers | 1 | 2012 | 3386 | 0.010 |
Why?
|